Functionality of albumin-derived perfluorocarbon-based artificial oxygen carriers in the Langendorff-heart^†

References

• Ashruf JF, Ince C, Bruining HA. 1999. Regional ischemia in hypertrophic Langendorff-perfused rat hearts. Am J Physiol Heart Circ. 277:H1532–H1539.
   PubMed Web of Science ®Google Scholar
• Assayang P, Charlemagne D, Marty I, Leiris J, Lompre AM, Boucher F, et al. 1998. Effects of sustained low-flow ischemia on myocardial function and calcium-regulating proteins in adult and senescent rat hearts. Cardiovasc Res. 38:169–180.
   PubMed Web of Science ®Google Scholar
• Bell RM, Mocanu MM, Yellon DM. 2011. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol. 50:940–950.
   PubMed Web of Science ®Google Scholar
• Bian Y, Chang TMS. 2015. A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume. Artif Cells Nanomed Biotechnol. 43:1–9.
   PubMed Web of Science ®Google Scholar
• Brunet J, Boily MJ, Cordeau S, Des Rosiers C. 1995. Effects of N-acetylcysteine in the rat heart perfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and nitric oxide-dependent increase in coronary flow. Free Radic Biol Med. 19:627–638.
   PubMed Web of Science ®Google Scholar
• Castro CI, Briceno JC. 2010. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs. 34:622–634.
   PubMed Web of Science ®Google Scholar
• Chang TMS. 2003. Future generations of red blood cell substitutes. J Intern Med. 253:527–535.
   PubMed Web of Science ®Google Scholar
• Chang TMS. 2015. Red blood cell replacement, or nanobiotherapeutics with enhanced red blood cell functions? Artif Cells Nanomed Biotechnol. 43:145–147.
   PubMed Web of Science ®Google Scholar
• Clark LC Jr, Kaplan S, Becattini F, Benzing G. 1970. Perfusion of whole animals with perfluorinated liquid emulsions using the Clark bubble-defoam heart-lung machine. Fed Proc. 29:1764–1770.
   PubMedGoogle Scholar
• Clark LC, Gollan F. 1966. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science. 152:1755–1756.
   PubMed Web of Science ®Google Scholar
• Dhein S, Mohr FW, Delmar M. 2005. The Langendorff Heart. Practical Methods in Cardiovascular Research. Berlin Heidelberg: Springer-Verlag, pp. 155–172.
   Google Scholar
• EPaE Council. 2010. European Commission (2010) Directive 2010/63/EU on Protection of Animals Used for Scientific Purposes. Ispra, Italy: Institute for Health and Consumer Protection.
   Google Scholar
• Flaim SF. 1994. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. Artif Cells Blood Substit Immobil Biotechnol. 22:1043–1054.
   PubMed Web of Science ®Google Scholar
• Fujino Y, Suzuki Y, Kakinoki K, Tanioka Y, Ku Y, Kuroda Y. 2003. Protection against experimental small intestinal ischaemia-reperfusion injury with oxygenated perfluorochemical. Br J Surg. 90:1015–1020.
   PubMed Web of Science ®Google Scholar
• Gale SC, Gorman GD, Jack G, Jack BS, Copeland MD, McDonagh PF. 2007. Perflubron emulsion prevents PMN activation and improves myocardial functional recovery after cold ischemia and reperfusion. J Surg Res. 138:135–140.
   PubMed Web of Science ®Google Scholar
• Haruki R, Kimura T, Iwasaki H, Yamada K, Kamiyama I, Kohno M. 2015. Safety evaluation of hemoglobin-albumin cluster ‘hemoact’ as a red blood cell substitute. Sci Rep. 5:12778.
   PubMed Web of Science ®Google Scholar
• Ingram DA, Forman MB, Murray JJ. 1993. Activation of complement by fluosol attributable to the pluronic detergent micelle structure. J Cardiovasc Pharmacol. 22:456–461.
   PubMed Web of Science ®Google Scholar
• Isaka M, Sakuma I, Imamura M, Makino Y, Fukushima S, Nakai K, et al. 2005. Experimental studies on artificial blood usage for hemodilution during cardiopulmonary bypass. Ann Thorac Cardiovasc Surg. 11:238–244.
   PubMedGoogle Scholar
• Isaka M, Sakuma I, Shiiya N, Fukushima S, Nakai K, Kitabatake A, et al. 2008. Experimental study of the relationship between perfluoro-octyl bromide emulsion and norepinephrine release in reperfusion arrhythmia: isolated guinea pig heart model. Ann Thorac Cardiovasc Surg. 14:363–368.
   PubMed Web of Science ®Google Scholar
• Keipert P, Otto S, Flaim SF, Weers JG, Schutt EA, Pelura TJ, et al. 1994. Influence of perflubron emulsion particle size on blood half-life and febrile response in rats. Artif Cells Blood Substit Immobil Biotechnol. 22:1169–1174.
   PubMed Web of Science ®Google Scholar
• Krebs HA, Henseleit K. 1932. Untersuchungen ueber die Harnstoffbildung im Tierkoerper. Hoppe-Seyler’s Z Physiol Chem. 210:33–36.
   Google Scholar
• Laudien J, Wrobeln A, Groß Heitfeld C, Linders J, Mayer C, Wilde B, et al. 2017. Albumin-derived perfluorocarbon-based artificial oxygen carriers: A physico-chemical characterization and first in vivo evaluation of biocompatibility. Eur J Pharm Biopharm, under revision.
   PubMed Web of Science ®Google Scholar
• Lowe KC. 2003. Engineering blood: synthetic substitutes from fluorinated compounds. J Tissue Eng. 9:389–399.
   Web of Science ®Google Scholar
• Martin SM, Laks H, Drinkwater DC, Stein DG, Barthel SW, Capouya ER, et al. 1992. Perfluorochemical reperfusion limits myocardial reperfusion injury after prolonged hypothermic global ischemia. Biomater Artif Cells Immobilization Biotechnol. 20:985–989.
   PubMed Web of Science ®Google Scholar
• Mattrey RF, Hilpert PL, Long CD, Long DM, Mitten RM, Peterson T. 1989. Hemodynamic effects of intravenous lecithin-based perfluorocarbon emulsions in dogs. Crit Care Med. 17:652–656.
   PubMed Web of Science ®Google Scholar
• McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. 1996. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 93:135–142.
   PubMed Web of Science ®Google Scholar
• McDonagh P, Cerney K, Hokama JH, Lai G, Gonzales R, Davis-Gorman G, et al. 2001. Perflubron emulsion reduces inflammation during extracorporeal circulation. J Surg Res. 99:7–16.
   PubMed Web of Science ®Google Scholar
• Nguyen CT, Desgranges F, Galanis N, Roy G, Mare T, Boucher S, et al. 2008. Viscosity data for Al2O3-water nanofluid-hysteresis: is heat transfer enhancement using nanofluids reliable? Int J Therm Sci. 47:103–111.
   Web of Science ®Google Scholar
• Pasdois P, Parker JE, Griffiths EJ, Halestrap AP. 2013. Hexokinase II and reperfusion injury: TAT-HK2 peptide impairs vascular function in Langendorff-perfused rat hearts. Circ Res. 112:e3–e7.
   PubMed Web of Science ®Google Scholar
• Phupoksakul T, Leuangsukrerk M, Numpiboonmarn P, Somwangthanaroj A, Janjarasskul T. 2015. Properties of poly(lactide)-whey protein isolate laminated films. J Sci Food Agric. 95:715–721.
   PubMed Web of Science ®Google Scholar
• Rahamathulla PM, Watanabe K, Ashraf M, Millard RW. 1985. Prevention of lactate production and myocyte injury in isolated rat hearts perfused with perfluorochemical emulsion. Exp Pathol. 28:157–165.
   PubMedGoogle Scholar
• Riess JG. 2001. Oxygen carriers (“blood substitutes”) – raison d'etre, chemistry, and some physiology. Chem Rev. 101:2797–2920.
   PubMed Web of Science ®Google Scholar
• Roser M, Fischer D, Kissel T. 1998. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charge on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 46:255–263.
   PubMed Web of Science ®Google Scholar
• Rosoff JD, Soltow LO, Vocelka CR, Schmer G, Chandler WL, Cochran RP, et al. 1998. A second-generation blood substitute (perfluorodichlorooctane emulsion) does not activate complement during an ex vivo circulation model of bypass. J Cardiothorac Vasc Anesth. 12:397–401.
   PubMed Web of Science ®Google Scholar
• Schäfer V, Briesen H, Rübsamen-Waigmann H, Steffan AM, Royer C, Kreuter J, et al. 1994. Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J Microencapsul. 11:261–269.
   PubMed Web of Science ®Google Scholar
• Schreckenberg R, Rebelo M, Deten A, Weber M, Rohrbach S, Pipicz M, et al. 2015. Specific mechanisms underlying right heart failure: the missing upregulation of superoxide dismutase-2 and its decisive role in antioxidative defense. Antioxid Redox Signal. 23:1220–1232.
   PubMed Web of Science ®Google Scholar
• Segel LD, Ensunsa JD. 1988. Albumin improves stability and longevity of perfluorochemical-perfused hearts. Am J Physiol. 254:H1105–H1112.
   PubMedGoogle Scholar
• Segel LD, Follette DM, Iguidbashian JP, Contino JP, Castellanos LM, Berkhoff HA, et al. 1994. Posttransplantation function of hearts preserved with fluorochemical emulsion. J Heart Lung Transplant. 13:669–680.
   PubMed Web of Science ®Google Scholar
• Sloviter HA, Kamimoto T. 1967. Erythrocyte substitute for perfusion of brain. Nature. 216:458–460.
   PubMed Web of Science ®Google Scholar
• Sothornvit R, Krochta JM. 2000. Oxygen permeability and mechanical properties of films from hydrolyzed whey protein. J Agric Food Chem. 48:3913–3916.
   PubMed Web of Science ®Google Scholar
• Spiess BD. 2009. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics. J Appl Physiol. 106:1444–1452.
   PubMed Web of Science ®Google Scholar
• Sutherland FJ, Hearse DJ. 2000. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 41:613–627.
   PubMed Web of Science ®Google Scholar
• Tsuchida E, Sou K, Nakagawa A, Sakai H, Komatsu T, Kobayashi K. 2009. Artificial oxygen carriers, hemoglobin vesicles and albumin − hemes, based on bioconjugate chemistry. Bioconjugate Chem. 20:1419–1440.
   PubMed Web of Science ®Google Scholar
• Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. 1982. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood. 59:1299–1304.
   PubMed Web of Science ®Google Scholar
• Weiskopf RB. 2010. Hemoglobin-based oxygen carriers: compassionate use and compassionate clinical trials. Anesth Analg. 110:659–662.
   PubMed Web of Science ®Google Scholar